Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of sacituzumab tirumotecan combined with SKB118 in locally advanced or metastatic non-small cell lung cancer
CTR20262708Phase 2Active
- Sponsor
- Sichuan Kelun-Biotech Biopharmaceutical
- Start
- Aug 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sacituzumab tirumotecan, CR-001 in non-small cell lung cancer (NSCLC), sponsored by Sichuan Kelun-Biotech Biopharmaceutical. Started Aug 2026; status: active.
02
Drugs
sacituzumab tirumotecanCR-001
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20262708.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262708.